Steady Expansion Forecast for Antipsychotic Drugs Market, Projected to Reach $31.04 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Antipsychotic Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of antipsychotic drugs has seen quick expansion over the recent past. $19.5 billion marked the market size in 2024, this is predicted to escalate to $21.45 billion in 2025, accompanied by a compound annual growth rate (CAGR) of 10.0%. The historical growth duration has witnessed elevation due to factors such as the surging incidence of mental health disorders, invention of second-generation antipsychotics, an enlarging elderly population, enhancement in healthcare infrastructure, and substantial funding in research and innovations.

Antipsychotic Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market for antipsychotic drugs is projected to experience robust expansion in the approaching years, with its size swelling to $31.04 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.7%. The upsurge during the forecast period can be linked to the escalating prevalence of mental ailments like schizophrenia and bipolar disorder, governmental support and subsidies, augmenting need for individualized treatment, efforts to reduce adverse effects, and the proliferation of advocacy and support groups for mental health. Noteworthy trends to watch over the forecast timeline encompass the application of digital health implements for monitoring, the breakthrough in innovative mechanisms of action, growing attention towards combination treatments, the embrace of pharmacogenomics for bespoke therapy, and a patient-centered approach to drug development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/antipsychotic-drugs-global-market-report

What Are the Drivers Transforming the Antipsychotic Drugs Market?
The escalation in instances of mental health concerns is anticipated to catalyze the expansion of the antipsychotic medication market. Mental illnesses, which often manifest as disruptions in a person's thinking patterns, behavior, mood, and overall mental welfare, can be instigated by a myriad of factors including elevated stress levels, societal pressures, genetic factors, biochemical imbalances, neurodevelopmental concerns, and physical health conditions. Antipsychotic medications function by modifying the action of neurotransmitters, predominantly dopamine and serotonin, thereby curbing psychotic symptoms, stabilizing mood, and enhancing cognitive and emotional capabilities. To illustrate, in November 2023, a study by the Substance Abuse and Mental Health Services Administration (SAMHSA), a public health government agency in the US, revealed that roughly 6% of adults over 18 years or about 15.4 million persons, had severe mental illness (SMI). Additionally, as per a September 2024 report by the Australian Institute of Health and Welfare, a government agency in Australia, the populace dealing with dementia is set to double from approximately 411,100 in 2023 to 849,300 by 2058, impacting 315,500 men and 533,800 women. Consequently, the increasing prevalence of mental health issues is fueling the growth of the antipsychotic medication market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18780&type=smp

What Long-Term Trends Will Define the Future of the Antipsychotic Drugs Market?
Several leading corporations in the antipsychotic drug market are focusing on introducing more advanced medical tools, such as subcutaneous atypical antipsychotic injections. These injections are designed to provide better patient compliance and increased effectiveness than traditional orally administered medications. These subcutaneous injectable psychiatric drugs, administered under the skin, aim to treat mental health conditions, maintain consistent blood levels and enhance symptom management. For instance, Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical organization, and MedinCell SA, a French biological product and pharmaceutical preparations manufacturer, launched the FDA-approved UZEDY in April 2023. This long-acting, subcutaneous injection of risperidone provides a flexible dosing interval of one or two months, leveraging MedinCell's proprietary SteadyTeq technology to steadily dispense the drug, reaching therapeutic levels within 6-24 hours after administration. In clinical studies, UZEDY showed up to an 80% drop in the risk of schizophrenia relapse, compared with the placebo. Thus, it is designed to tackle adherence issues typically linked with oral antipsychotics, often resulting in relapse.

Which Segments in the Antipsychotic Drugs Market Offer the Most Profit Potential?
The antipsychotic drugs market covered in this report is segmented -

1) By Therapeutic Class: First Generation, Second Generation, Third Generation
2) By Disease: Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Drug Stores, Online Pharmacies

Subsegments:
1) By First Generation: Typical Antipsychotics, Phenothiazines, Butyrophenones, Thioxanthenes, Dibenzoxazepines
2) By Second Generation: Atypical Antipsychotics, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripiprazole, Paliperidone, Lurasidone
3) By Third Generation: Partial Dopamine Agonists, Aripiprazole, Brexpiprazole, Cariprazine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18780&type=smp

Which Firms Dominate the Antipsychotic Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

Which Regions Offer the Highest Growth Potential in the Antipsychotic Drugs Market?
North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18780

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.